TBL 100
Alternative Names: TBL-100Latest Information Update: 28 May 2023
At a glance
- Originator Northwest University
- Developer LifeArc; TAU BIO-LOGIC
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Progressive supranuclear palsy
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Progressive-supranuclear-palsy in USA (Parenteral)
- 08 May 2019 TBL 100 licensed to Tau-Biologics worldwide (Tau-biologics pipeline, May 2019)